Cortexolone-17a-propionate is a topical antiandrogen under investigation for the treatment of androgenrelated skin disorders. A full conformational characterization was realized, in comparison with other steroidal androgens and antiandrogens, by means of theoretical calculations at the B3LYP/6-31G(d) level supported by high-field NMR analyses. All of the studied molecules showed a good overlay; nevertheless, the different functional groups present in the skeleton of the molecules drive the individual biological profile.
Introduction
The skin's capability of synthesizing and converting androgens is well documented.
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The 5a-reductase-catalyzed transformation of testosterone 1 affords dihydrotestosterone (DHT, 2) (Fig. 1) , the most active metabolite involved in many androgen-related skin disorders such as hirsutism, androgen alopecia and acne. [1] [2] [3] [4] [5] The treatment of these disorders can be realized by either inhibiting the 5a-reductase or antagonizing the binding of testosterone and DHT at the androgen binding sites. 6 Known androgen antagonists, such as nasteride 6 or cyproterone acetate 7, when systemically administered, show benecial effects in the management of these skin disorders together with an interference with the hormonal environment in male and female patients. 7 Several years ago we investigated 8 the antiandrogenic activity of a family of 17a-esters of cortexolone (17a,21-dihydroxy-4-pregnene-3,20-dione 3), an intermediate of the glucocorticoid biosynthesis, devoid of endocrine function, with the exception of a weak glucocorticoid activity.
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Among the studied esters, 17a-propionate 4 showed a strong local antiandrogenic activity in the hamster ank organ test 10 being, on the contrary, ineffective when subcutaneously injected by repeated administrations in animals even at very high doses. 8 The systemic antiandrogenic activity of 17a-propionate of cortexolone was assessed by its ability to decrease the weight of the androgen-dependent organs (ventral prostate, seminal vesicles and preputial glands) stimulated by the injection of testosterone propionate (TP). 8 The absence of systemic antiandrogenic effects could be explained considering that the propionate, aer percutaneous application, is quickly hydrolyzed by the skin and plasma esterases into the inactive parent cortexolone (3) getting through the 21-propionate 5.
The topical activity of compound 4 is higher than that of nasteride 6 and about equivalent to that of cyproterone acetate 7. Taking into account the topical activity of propionate 4 coupled with the lack of systemic activity, we planned to compare this 17a-ester with the well-known antiandrogen cyproterone acetate 7 and with the natural androgens, testosterone 1 and dihydrotestosterone 2, from a conformational point of view.
In fact, the conformation of a biologically active compound plays a central role when it interacts with the target, for example, a receptor or an enzyme; among the possible conformations only one could be able to stimulate the biological response as we also reported in a previous work.
11 The choice of the compounds to be compared with propionate 4 was driven by its antiandrogenic activity. In fact testosterone (1) and dihydrotestosterone (2) are antagonized both by compounds 4 and 7 with the same action mechanism that does not implicate the interference with the 5a-reductase. The conformational characterization was realized by means of theoretical calculations, validated by complete assignment of the 1 H and 13 C NMR signals, as in the case of our previous studies of steroidal compounds.
11

Results and discussion
Biological activity of cortexolone-17a-propionate (4)
Local activity and mechanism of action of cortexolone-17a-propionate (4). The local activity of 4 was established by means of the hamster ank organ test. 8 The results are summarized in Table 1 (for a more exhaustive discussion see ref. 8) . The antiandrogenic activity of 4 is dose-related; the parent cortexolone (3) is devoid of effect; when compared to other androgen antagonists, administered at a xed dose (400 mg), compound 4 resulted in being two times more active than nasteride (6) and about as active as cyproterone acetate (7) .
As concerns the mechanism of action, compound 4, compared to nasteride (6) the well-known inhibitor of 5a-reductase, did not inhibit the conversion of testosterone (1) to DHT (2) Systemic activity of cortexolone-17a-propionate (4). Systemic antiandrogenic activity of 4 was evaluated in male castrated rats primed with TP. Aer repeated subcutaneous injections of 0.2-1 and 5 mg per animal, compound 4 was completely unable to antagonize the stimulating effect of TP on the target organs ventral prostate, seminal vesicles, and preputial glands. 8 Also, parent cortexolone (3) resulted in being devoid of activity in this test.
8 Compound 4 was also endowed with glucocorticoid activity (adrenals and thymus weight inhibition), detectable only at the highest tested dose equivalent to about 100 mg per kg of body weight. Considering the very high dose required to obtain the glucocorticoid activity, this effect should be minimal and of little importance when the product is administered by topical route. 8 In addition, in the antigonadotropic activity test 17a-propionate 4, even injected at the highest dose, was completely devoid of activity on gonadotropin hypersecretion, as compared to progesterone. These data demonstrate that compound 4 is a peripherally selective antiandrogen not affecting the CNS. Metabolism of cortexolone-17a-propionate (4) . The absence of systemic activity can be explained by a rapid hydrolysis of the 17a-ester affording the inactive cortexolone (3). Cortexolone17a-propionate (4), when incubated in rat plasma, was rapidly converted (50%) to free cortexolone (3) within 2 h of incubation and completely metabolized within 8 h ( Table 2 ). The acyl group initially undergoes a non-enzymatic migration to the 21-position and subsequently an esterase-catalyzed hydrolysis affording the inactive cortexolone (3). The formation of intermediate 5 was investigated by incubating 4 at 37. 8 C for up to 8 h in the absence or presence of 50 mg mL À1 of enzymatic inhibitor dichlorvos. When the incubation was performed in the presence of the inhibitor, a large amount of cortexolone-21-propionate (5) was detected, thus conrming that the biotransformation of 17a-propionate 4 to cortexolone (3) takes place by the production of 21-propionate 5, as an effect of non-enzymatic migration of the propionyl group from the 17a-position to the 21-position, and subsequent hydrolysis of the 21-propionate (5) to cortexolone (3). An analogous metabolic prole of 4 was observed with incubation in human plasma (Table 3) .
In rat skin homogenate the metabolic transformation of 4 to cortexolone (3) reached a peak (40-44.7%) within 8-16 h, and remained stable during the remnant incubation period of up to 24 h (Table 4) .
Biological activity of cortexolone-21-propionate (5) and cortexolone-17a,21-dipropionate (8) . In Table 5 is reported the local antiandrogenic activity of compounds 5 and 8, showing in the ability of the tested steroids (400 mg) to inhibit the enlargement of the hamster ank organ test, in turn produced by the administration of TP (4 mg). The 21-monoesterication of cortexolone (3) leads to compound 5 being nearly devoid of activity, like the parent cortexolone (3). The 17a,21-diesterication (compound 8) reduces the antiandrogenic activity granted by the 17a-esterication of compound 4 (84% inhibition, Table 1 ).
Biological activity of 9,11-dehydrocortexolone-17a-butyrate (9). The 9,11-dehydrocortexolone-17a-butyrate (9), based on the results of the screening phase, was identied as the most potent topical antiandrogen among the 17a-monoesters; in fact, it showed an 85% ability to inhibit the enlargement of the hamster's ank organ produced by topical administration of TP (Table 5) , whereas the corresponding saturated 17a-butyrate showed a 76% ability.
Differently from the 17a-monoesters of cortexolone, 9,11-dehydrocortexolone-17a-butyrate (9) was found to show systemic activity in the rat aer subcutaneous injection.
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Compound 9 was also discovered to be a potent inhibitor of gonadotropin hypersecretion, thus mimicking the activity prole of cyproterone acetate (7), which blocks the androgenreceptor interaction and simultaneously reduces serum testosterone through its antigonadotropic action. 13, 14 The presence of a double bond at position 9,11 of the cortexolone, modifying the spatial conformation of the steroids rings, could be responsible for the systemic and increased topical activity of 9. 12 
Conformational properties
The above observations prompted us to study the conformational properties of compound 4 and of the related compounds to establish and compare their preferred conformations. To this end, other known androgenic or antiandrogenic steroids were simultaneously analyzed including testosterone (1) and its most potent metabolite DHT (2) active in the skin, cortexolone (3) and its derivatives 8 and 9 and cyproterone acetate (7) .
Conformational properties of compounds 1 and 2. An extensive exploration of the conformational space of compounds 1 and 2 was carried out through DFT calculations at the B3LYP/6-31G(d) level. Attention was focused on the tetracyclic system and on the possibility of inversion of the hexacyclic rings. Compound 1 prefers conformation 1A in which ring A assumed a half-chair geometry due to the presence of the double bond between C4 and C5. Conformation 1Ab differs from 1A ( Fig. 3 ) only in the orientation of the hydroxyl group at C17 and it is less stable by 0.27 kcal mol À1 . These two geometries account for more than 97% of the overall population ( Table 6 ). The inversion of ring A (1B) resulted in a geometry less stable by about 2 kcal mol À1 , whereas inversion of rings B and C gave two geometries (1C, 1D) less stable by 6.05 and 11.13 kcal mol À1 , respectively (Table 6 ). Concerning compound 2, the preferred conformation A showed the expected chair geometry of the hexacyclic rings and a twisted geometry of ring D. The inversion of ring A is easier than the others, but the corresponding conformation (2B) is less stable by more than 3 kcal mol À1 , leaving 2A and the analogous 2Ab conformation the only ones signicantly populated; in fact, they account for more than 99% of the overall population. These two geometries differ only in the orientation of the hydroxyl group at C17 that has two accessible orientations with a small difference in energy (0.31 kcal mol À1 ). The preferred one is that with s 1 z 170 (2A) (Fig. 3 and Table 6 ). Some short contacts characterize the conformational preferences of the rings of 2: H-2ax/CH 3 -10 (2.81Å), and H-4ax/CH 3 -10 (2.76Å) for the A ring; H-6ax/CH 3 -10 (2.72Å), H-8ax/CH 3 -10 (2.86Å) for the B-ring conformation; H-11ax/CH 3 -10 (2.73Å), H-11ax/CH 3 -13 (2.76Å), and H-8ax/CH 3 -13 (2.78Å) for the C ring; H-15ax/CH 3 -13 (2.90Å) for ring D.
Conformational properties of compounds 3, 4 and 7-9. The conformational space of compounds 3, 4, 7, 8 and 9 was analyzed at the same level as above. Analogously to 1, ring A presents, in all cases, an unsaturation between C4 and C5 that forces it to assume a half-chair geometry. In Table 6 the most representative conformations are reported. The preferred conformation of compounds 3, 4, 7, 8 and 9 (Fig. 4 and 5) , located in the present study, corresponds, in the tetracyclic skeleton, to the geometry already determined at the same level of calculations for progesterone and a group of 13-ethylsteroids and related estrogens modeled in previous papers. 11 In fact, as can be seen from Table 6 , they show very close values of torsional angles (s A-C ) and puckering coordinates.
The energy proles for rotation around the C17-C20, and C17-O single bonds, dened by s 1 and s 2 , were obtained and the preferred orientations determined. The C17-C20 bond showed a quite balanced distribution of its possible orientations, with the presence, for all compounds, of two signicantly populated geometries that present s 1 z 160, and s 1 z À10, respectively. For 3 and 8 conformation Ab, with s 1 z À10, is favoured by 0.63 and 1.29 kcal mol À1 , respectively, whereas 4 and 9 prefer the other orientation by 0.46 and 0.25 kcal mol À1 , respectively.
Concerning the C17-O bond, in the case of 4, 8, and 9, a signicant preference was observed for the orientation characterized by s 2 z À60 , with the other higher in energy by 4-6 kcal mol À1 , whereas in 3 the hydroxyl group bonded at C17
shows two orientations related to the value of s 1 , being preferred s 2 ¼ À45 for s 1 ¼ 146, and s 2 ¼ À159 for s 1 ¼ À24. In compound 8, the hydroxyl at C21, present in 3, 4, and 9, is esteried, with the generation of a second propionate group. Considering the oxoethyl propionate bonded at C17 the torsional angle s 3 describes the relative orientation of the two carbonyl groups of the chain. The second one is perpendicular to the rst (s 3 z 90 ), whatever the orientation of this latter (see s 1 ). A careful analysis of the conformational freedom of the tetracyclic skeleton allowed us to determine the facility of inversion of the three hexacyclic rings. The A ring inversion from the 1a,2b-half-chair to the 1b,2a-half-chair conformation (3, 4, 8, 9A / 3, 4, 8, 9B) is the easiest among all the possible ring inversions. In the case of compounds 3, 4, and 8, the A ring inversion brings about a conformation less stable by about 2 kcal mol À1 .
For compound 9 the same inversion is easier, giving the conformation 9B with an energy value of 1.34 kcal mol À1 . So the percentage contribution of the 1b,2a-half-chair conformation to the overall population is double in the case of 9 with respect to the others, although the 1a,2b-half-chair conformation remains widely preferred.
As regards B ring inversion, the obtained conformations C, presenting a relative energy of about 4-6 kcal mol À1 , respectively, do not give any contribution to the overall population. The ring C inversion of 9 is not possible because of the presence of the double bond, whereas for 3, 4 and 8 a conformation (D) is obtained that is higher in energy than the global minimum by more than 10 kcal mol À1 .
In 3, 4, 8 and 9 the preference of ring A for the 1a,2b-halfchair conformation is characterized by the short contact H-2ax/ CH 3 Compound 7 shows a rigid structure and the only degree of conformational freedom is the inversion of ring C. Rings A and B could not be inverted because of the presence of the cyclopropane ring and the double bond, respectively. Nevertheless, the C ring inversion gave conformations with a relative energy of about 13 kcal mol À1 , giving no contribution to the overall population. So, only two geometries, 7A and 7Ab, are populated (Fig. 5) . Conformation A of compound 7 presents the following contacts: H-11b/CH 3 -18 (2.24Å), H-11b/CH 3 -19 (2.29Å), H-8/ CH 3 -19 (2.76Å), and H-9/CHa-cPr (2.66Å). On the basis of crystallographic studies 15 performed on dihydrotestosterone (2) complexed with the ligand-binding domain of the wild-type androgen receptor, both the carbonyl oxygen atom bonded at C3 and the hydroxyl group at C17 of this molecule actively contribute to the stabilization of the obtained complex. The A ring conformation inuences the orientation of the carbonyl group that deeply affects the binding of the entire molecule.
A docking study performed on 7, 16 into the homology model for the glucocorticoid receptor ligand binding domain, revealed that in the active site it assumes conformation A.
The superimposition of the heavy atoms of the tetracyclic system of the preferred conformations of compounds 3, 4 and 7-9 ( Fig. 6) gave evidence that the presence of the hydroxyl group or the ester chain, bonded to C21 in compounds 3, 4, 8 and 9, does not affect the orientation of the substituent at C17.
Compounds 3, 4, 8 and 9 show a very good overlay, also concerning the O3 atoms that are perfectly coincident, in spite of the presence in 9 of a double bond on ring C. Conversely, the overlay shows that in 7 the O3 atom is differently oriented and diverges with the distance d(O-O) z 1.0Å.
NMR data
Complete 1 H and 13 C NMR signal assignments (Tables 7-9 ) of the spectra of compounds 3, 4 and 7-9 were achieved using a combination of 1D and 2D (COSY, HSQC and NOESY) experiments recorded in CDCl 3 at 298 K. In general, starting from characteristic H-4, H-7 or H-11 olenic protons it was possible to assign the resonances of all the other protons of the studied steroids on the basis of their 2D spectra. First of all, H-8 was assigned through COSY correlations from H-4 of compounds 3, 4, 8 and 9 or from H-7 of compound 7. Then, it was possible to discriminate between H-9 and H-14 (showing two very clear and distinctive HSQC cross-peaks accounting for C-H protons) on the basis of H-9/H-11 coupling, with H-11b being assigned on the basis of its NOESY cross-peak with 19-CH 3 (previously distinguished from 18-CH 3 that showed a NOESY correlation with the characteristic 21-protons). Also, H-1, and consequently H-2, resonances were assigned through the NOESY cross-peak of H-1b and 19-CH 3 . Finally, analysis of the 18-and 19-CH 3 NOESY cross-peak network was especially useful for the assignment of the a-or b-conguration of geminal protons (see Table 7 ) of all the studied compounds. Even if some protons in the 1 H NMR spectra resonated as complex multiplets (see Table   7 ), many signals were well resolved and their coupling could be measured. The obtained values are reported in Table 9 in comparison with the calculated constants of compounds 3, 4 and 7-9. For each populated conformer the 1 H vicinal coupling constants were calculated with the electronegativity-modied Karplus relationship 17 and were weight-averaged on the basis of the population percentages. The experimental and the calculated values resulted in close agreement. The following nuclear Overhauser effect (nOe) contacts were observed in the NOESY spectra of the studied compounds. a Ability of the tested steroids (400 mg) to inhibit the enlargement of the hamster's organ ank produced by the administration of 4 mg of testosterone propionate. conformations. In particular, almost all these contacts correspond to distances of <3Å as measured on the computed (Fig. 4 and 5 ) most populated conformations of compounds 3, 4 and 7-9.
Discussion
Cortexolone-17a-propionate (4) is a steroid endowed with a strong local antiandrogenic activity but it is devoid of systemic antiandrogenic activity and it does not affect the hypersecretion of gonadotropins. Cortexolone-17a-propionate (4) does not inhibit the conversion of testosterone (1) to DHT (2) in reconstructed human epidermis, thus resulting in being devoid of activity on the 5a-reductase. Nevertheless, compound 4 competes with the androgens at the androgen receptor level, and thus its strong antiandrogenic activity is attributable to this mechanism of action. As a consequence it is under investigation in the management of acne and alopecia.
In the present work a conformational comparison of 4 with testosterone (1), active testosterone metabolite DHT (2) and antiandrogen cyproterone acetate (7) (similar to 4 for the action mechanism direct on the androgen receptor) was carried out by means of theoretical calculations, supported by their complete high-eld NMR characterization. In addition, the comparison was extended to the related compounds cortexolone (3), devoid of activity, cortexolone-17a,21-dipropionate (8), less active, and D 9 -butyrate 9, active both topically and systemically.
The conformational characterization showed that all compounds are similar (see Fig. 6 ), minor differences being observed: cyproterone acetate (7) has the 3-carbonyl group differently oriented and the presence of the 9,11-double bond hampers the C ring inversion in compound 9. However the 3-carbonyl group orientation (7 vs. 4, Table 1 ) and the conformation of the C ring (9 vs. 4, Tables 1 and 5) do not inuence the extent of the local antiandrogenic activity of the Table 6 Geometrical features, relative energies, and equilibrium percentages of the selected conformations of compounds 1-4 and 7-9 tested compounds. By contrast, the presence of the 17a-ester group, which was always oriented in the same way from the conformational study, seems to be mandatory for a good inhibitory activity (3 vs. 4, Table 1 ). In conclusion, the cortexolone series compounds 3-5 and 8, cyproterone acetate (7), and D 9 -17a-butyrate 9 share the same skeleton conformation but show different antiandrogenic activities due to the presence of an acyl chain linked to the 17a-hydroxyl functionality.
The same skeleton conformation of the examined compounds is consistent with the capability of each of them to interact, even with different outcomes, with the androgen receptors. Furthermore, the absence of systemic activity of 4 could be explained by its metabolic fate, i.e. the esterases-catalyzed hydrolysis of the acyl chain, aer the rapid migration from the 17-to the 21-position.
Experimental
Materials and methods
All the cortexolone derivatives were from an internal source. Others steroids, Sephadex LH-20 and all reagents and solvents were purchased from Sigma Aldrich, Milan (Italy); Extrelut ® NT columns were obtained from Merck.
Biological tests
Animals. Female Syrian golden hamsters and Wistar Han rats of both sexes (Charles River, Italy) were used in the experiments. The experiments were approved by the local Institutional Ethical Committee, and were conducted in agreement with the EEC Directive 86/609 and with the Italian Legislative Decree 116/27.01.1992 concerning the protection of animals used for experimental purpose or other scientic scope.
Hamster ank organ test. Female Syrian golden hamsters, 60-90 g body weight, were treated for 21 consecutive days with cortexolone-17a-propionate (4) and related compounds 5, 8, 9 applied directly onto the right ank organ at a daily dose ranging from 100 to 400 mg. The products were dissolved in 0.05 mL acetone solution containing 4 mg of TP. Parent cortexolone (3), progesterone, cyproterone acetate (7) and nas-teride (6) were also tested. Control groups of animals treated with TP alone have also been included. The antiandrogenic activity of the compounds was assessed by their ability to reduce the enlargement of the ank organs induced by TP alone.
Systemic antiandrogenic and glucocorticoid activity. Male castrated Wistar rats, 45-50 g body weight, were subcutaneously injected, for seven consecutive days, with cortexolone17a-propionate (4) or with 9,11-dehydrocortexolone-17a-butyrate (9) (0.2-1 and 5 mg), and with 40 mg of TP. Parent cortexolone (3) was also tested at a daily dose of 5 mg. Control groups of untreated or treated animals with TP alone were also included. The antiandrogenic activity of 4 and 9 was evaluated by their ability to antagonize the androgenic effect induced by TP on the target androgenic organs: ventral prostate, seminal vesicles, and preputial glands. The weight reduction of adrenals and thymus was assumed as the glucocorticoid activity index.
Antigonadotropic activity. Wistar rats of both sexes, 50-60 g body weight, were employed. The males were castrated and, on the following day, they were surgically joined with intact females in latero-lateral parabiosis. In this model the castration induces a prompt increase of male gonadotropins which, in turn, reach the intact partner females and stimulate the ovarian growth. Starting on the day aer parabiosis, each male was subcutaneously injected with cortexolone-17a-propionate (4) or with 9,11-dehydrocortexolone-17a-butyrate (9) at doses of 1 and 5 mg. Progesterone was assumed as the standard control and was administered, using the same procedure, at doses of 0.5 and 2 mg. The treatment lasted for eight consecutive days, aer which the couples were autopsied. The ovaries were isolated and weighed. The inhibitory activity against gonadotropin hypersecretion, induced by castration in the males, was evaluated by the ability of 4 and 9 to antagonise the ovarian weight increase.
Metabolism
Metabolism in rat and human plasma. Samples of rat plasma were incubated at 37. 8 C with cortexolone-17a-propionate (4) (0.4 mg mL À1 ) for 8 h in the presence or absence of 50 mg of enzymatic inhibitor dichlorvos. Determination of 4, free cortexolone (3), and cortexolone-21-propionate (5) were carried out at 5, 15, and 30 min and 1, 2, 4, and 8 h incubation periods by HPLC. Samples of human plasma were incubated with cortexolone-17a-propionate (4) (0.4 mg mL À1 ) at 37.8 C for 6 h. Determination of 4, free cortexolone (3), and cortexolone-21-propionate (5) was performed at 30 min and 1, 2, 4, and 6 h incubation periods by HPLC. Metabolism in rat skin homogenate. Dorsal skin samples of male rats (Harlan Laboratories, Italy) were homogenised and incubated at 36. 5 C with cortexolone-17a-propionate (4) (0.4 mg mL À1 ). Determination of 4, free cortexolone (3) and cortexolone-21-propionate (5) were done at 30 min and at 1, 4, 8, 16 , and 24 h incubation periods by HPLC. 
